MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2026-27)
- Udyam number
- UDYAM-TS-02-0005626
Market Cap
₹215 Cr
GENNEX · BSE
Share Price
₹8.70
-1.69% today
Revenue
₹173 Cr
FY 2025-26 · +25.3% YoY
EBITDA
₹21.84 Cr
Margin 12.6%
Net Profit
₹19.00 Cr
FY 2025-26 · +4.1% YoY
P/E (TTM)
11.5x
P/B 1.0x
Authorised capital
₹25 Cr
Registered with MCA
Paid-up capital
₹24.29 Cr
Issued & subscribed
About Gennex Laboratories Limited
Data last updated:
Gennex Laboratories Limited is a public limited company based in Medak, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 29 March 1990 and has been in existence for over 36 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24230TG1990PLC011168. The company has 2 GST registrations on record, none of which is active. It is a listed company as per MCA records. Its shares are listed on BSE: 531739.
The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹24.29 Cr. It was formerly known as Prudential Pharmaceuticals Limited and Pharmasia Drugs and Chemicals Private Limited. It is led by directors including Arihant Baid (Managing Director) and Ranga Rao Pantulu Avasarala.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 133 Bollaram Jinnaram, Medak, Telangana, India – 502325.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹172.74 Cr, a growth of 25.3% compared to the previous year. For the same year it recorded a net profit of ₹19 Cr (net margin 11%) and EBITDA of ₹21.84 Cr (EBITDA margin 12.6%). The net worth stands at ₹222.52 Cr (up 19.2% YoY). Total assets are valued at ₹312.2 Cr (up 40.8% YoY).
The company has about 103 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Gennex Laboratories. As per MCA filings, the company has open charges of ₹66 Cr and satisfied charges of ₹26.13 Cr on record. Court records list 30 cases involving the company, including 18 filed by the company and 12 filed against it; 3 cases are pending. The company has 160 deals on record (158 market trades, 2 rights issues); the latest was in May 2026. Its 8 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 5 smaller; the largest is Angels Pharma India Private Limited with revenue of ₹94.49 Cr.
Gennex Laboratories Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0005626). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website gennexlab.com.
Company details
CIN L24230TG1990PLC011168
Registration Number 011168
Incorporation Date 29 March 1990
ROC Hyderabad
Listing Status Listed - Listed on BSE (531739)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TS-02-0005626
Name history
Gennex Laboratories has undergone 3 name changes throughout its history. The company was previously known as Prudential Pharmaceuticals Limited, Pharmasia Drugs And Chemicals Private Limited, and Pharmasia Drugs And Chemicals Limited. The current legal name is Gennex Laboratories Limited.
| Company Name | Status |
|---|---|
| Gennex Laboratories Limited | Current |
| Prudential Pharmaceuticals Limited | Previous |
| Pharmasia Drugs And Chemicals Private Limited | Previous |
| Pharmasia Drugs And Chemicals Limited | Previous |
CIN history
Gennex Laboratories has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230TG1990PLC011168, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230TG1990PLC011168 | Current |
| L24230AP1990PLC011168 | Previous |
| L24230AP1990PTC011168 | Previous |
Key People
Arihant Baid Managing Director Ranga Rao Pantulu Avasarala Director Amudala Sreeramulu Nageswar Rao Director Recognitions & Rankings of Gennex Laboratories
Contact details
Gennex Laboratories Limited's registered office is in Medak, Telangana. Its website is gennexlab.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address133 Bollaram Jinnaram, Medak, Telangana, India – 502325
- IndustryPharma, API Manufacturers
To see the full contact details of Gennex Laboratories Limited, buy the company report.
Comprehensive company report
Gennex Laboratories Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Gennex Laboratories operates one associated brand: Gennex Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| APIs are manufactured, marketed, and exported by Gennex Laboratories. | gennexlab.com |
Business activity
The main business activity of Gennex Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Gennex Laboratories Limited, buy the company report.
Financials of Gennex Laboratories Limited
FY 2025-26 filings availableGennex Laboratories Limited reported revenue of ₹172.74 Cr (up 25.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹173 Cr
+25.3% YoY
EBITDA
₹21.84 Cr
+31.9% YoY
Profit After Tax
₹19.00 Cr
+4.1% YoY
Net Worth
₹223 Cr
+19.2% YoY
Total Assets
₹312 Cr
+40.8% YoY
Total Debt
₹35.95 Cr
+251.8% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 173 | 138 | 86.71 | 65.61 | 61.21 | 59.65 | 55.62 |
| Revenue growth | +25.3% | +59.0% | +32.2% | +7.2% | +2.6% | +7.3% | - |
| EBITDA | 21.84 | 16.56 | 17.03 | 4.70 | 5.37 | 6.16 | 3.25 |
| EBITDA margin | +12.6% | +12.0% | +19.6% | +7.2% | +8.8% | +10.3% | +5.8% |
| Profit before tax | 23.24 | 21.39 | 16.49 | 6.38 | 5.08 | 5.06 | 2.56 |
| Net profit | 19.00 | 18.26 | 12.71 | 4.89 | 3.91 | 4.32 | 1.79 |
| Net profit margin | +11.0% | +13.2% | +14.7% | +7.5% | +6.4% | +7.2% | +3.2% |
| EPS (₹) | 0.76 | 0.80 | 0.58 | 0.27 | 0.31 | 0.32 | 0.15 |
| Balance sheet | |||||||
| Total assets | 312 | 222 | 195 | 104 | 53.94 | 47.09 | 40.67 |
| Net worth | 223 | 187 | 170 | 80.35 | 43.81 | 39.71 | 35.67 |
| Total debt | 35.95 | 10.22 | 5.72 | 1.05 | 10.12 | 7.36 | 4.98 |
| Cash & bank | 52.42 | 55.57 | 60.97 | 15.06 | 8.31 | 1.07 | 0.91 |
| Net working capital | 228 | 147 | 127 | 20.22 | 33.10 | 26.01 | 19.09 |
| Cash flow | |||||||
| Cash from operations | (63.65) | (9.56) | (46.69) | 23.68 | 11.91 | (1.44) | (1.67) |
| Cash from investing | (4.80) | 2.63 | 18.91 | (38.33) | (2.47) | (0.02) | (0.22) |
| Cash from financing | 65.30 | 1.53 | 73.68 | 21.03 | (1.83) | 1.62 | (0.35) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39.84 | 60.96 | 42.96 | 39.30 | 34.18 | 40.33 | 40.01 | 33.38 |
| Revenue growth (YoY) | +16.6% | +51.2% | +7.4% | +17.7% | +20.7% | - | - | - |
| Other income | 2.01 | 1.32 | 0.00 | 0.00 | 2.28 | 3.83 | 0.00 | 0.00 |
| EBITDA | 4.38 | 5.59 | 8.28 | 7.55 | 5.07 | 1.87 | 7.16 | 7.45 |
| EBITDA margin | +11.0% | +9.2% | +20.5% | +20.3% | +14.8% | +4.6% | +19.0% | +23.6% |
| Depreciation | 0.90 | 1.16 | 0.52 | 0.47 | 0.50 | 0.54 | 0.50 | 1.11 |
| Interest | 0.57 | 1.08 | 1.11 | 1.03 | 0.98 | 1.20 | 0.84 | 0.22 |
| Profit before tax | 4.92 | 4.67 | 6.65 | 6.05 | 5.87 | 3.96 | 5.82 | 6.12 |
| Tax | 0.25 | 0.21 | 0.65 | 0.55 | 0.85 | 0.88 | 0.75 | 0.75 |
| Net profit | 4.67 | 4.46 | 6.00 | 5.50 | 5.02 | 3.08 | 5.07 | 5.37 |
| EPS (₹) | 0.19 | 0.16 | 0.22 | 0.21 | 0.21 | 0.14 | 0.22 | 0.21 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 120 | 94.58 | 66.80 | 65.10 | 61.21 | 59.65 | 55.62 |
| Revenue growth | +26.7% | +41.6% | +2.6% | +6.4% | +2.6% | +7.3% | - |
| EBITDA | 13.53 | 10.19 | 12.43 | 4.59 | 5.37 | 6.16 | 3.25 |
| EBITDA margin | +11.3% | +10.8% | +18.6% | +7.1% | +8.8% | +10.3% | +5.8% |
| Profit before tax | 18.23 | 17.06 | 14.76 | 6.02 | 5.08 | 5.06 | 2.56 |
| Net profit | 16.65 | 14.18 | 11.80 | 4.53 | 3.91 | 4.32 | 1.79 |
| Net profit margin | +13.9% | +15.0% | +17.7% | +7.0% | +6.4% | +7.2% | +3.2% |
| EPS (₹) | 0.67 | 0.62 | 0.52 | 0.25 | 0.31 | 0.32 | 0.15 |
| Balance sheet | |||||||
| Total assets | 245 | 191 | 173 | 81.29 | 54.12 | 47.25 | 40.85 |
| Net worth | 218 | 185 | 171 | 79.02 | 44.00 | 39.89 | 35.85 |
| Total debt | 22.82 | 1.24 | 0.85 | 0.98 | 10.12 | 7.36 | 4.98 |
| Cash & bank | 52.40 | 55.56 | 60.96 | 14.45 | 8.31 | 1.07 | 0.91 |
| Net working capital | 209 | 159 | 147 | 57.22 | 33.10 | 25.99 | 19.09 |
| Cash flow | |||||||
| Cash from operations | (40.18) | (9.52) | (33.43) | (14.45) | 6.64 | (1.44) | (1.67) |
| Cash from investing | 1.62 | 2.63 | 0.93 | (0.77) | (1.26) | (0.02) | (0.22) |
| Cash from financing | 35.40 | 1.53 | 79.01 | 21.35 | 1.87 | 1.62 | (0.35) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.68 | 36.71 | 30.72 | 31.37 | 25.64 | 23.28 | 27.35 | 26.51 |
| Revenue growth (YoY) | +35.3% | +57.7% | +12.3% | +18.3% | +20.2% | - | - | - |
| Other income | 2.00 | 1.30 | 0.00 | 0.00 | 2.26 | 2.87 | 0.00 | 0.00 |
| Total expenses | 31.72 | 33.83 | 24.86 | 25.37 | 22.26 | 23.21 | 21.78 | 20.98 |
| EBITDA | 2.96 | 2.88 | 5.86 | 6.00 | 3.38 | 0.07 | 5.57 | 5.53 |
| EBITDA margin | +8.5% | +7.8% | +20.8% | +20.5% | +13.2% | +0.3% | +22.0% | +22.4% |
| Depreciation | 0.24 | 0.35 | 0.21 | 0.21 | 0.20 | 0.53 | 0.20 | 0.05 |
| Interest | 0.51 | 0.63 | 0.69 | 0.55 | 0.59 | 0.23 | 0.41 | 0.47 |
| Profit before tax | 4.21 | 3.20 | 4.96 | 5.24 | 4.85 | 2.18 | 4.96 | 5.01 |
| Tax | 0.25 | 0.21 | 0.50 | 0.70 | 0.70 | 0.67 | 0.75 | 0.85 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 24 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39.84 | 60.96 | 42.96 | 39.30 | 34.18 | 40.33 | 40.01 | 33.38 |
| Revenue growth (YoY) | +16.6% | +51.2% | +7.4% | +17.7% | +20.7% | - | - | - |
| Other income | 2.01 | 1.32 | 0.00 | 0.00 | 2.28 | 3.83 | 0.00 | 0.00 |
| EBITDA | 4.38 | 5.59 | 8.28 | 7.55 | 5.07 | 1.87 | 7.16 | 7.45 |
| EBITDA margin | +11.0% | +9.2% | +20.5% | +20.3% | +14.8% | +4.6% | +19.0% | +23.6% |
| Depreciation | 0.90 | 1.16 | 0.52 | 0.47 | 0.50 | 0.54 | 0.50 | 1.11 |
| Interest | 0.57 | 1.08 | 1.11 | 1.03 | 0.98 | 1.20 | 0.84 | 0.22 |
| Profit before tax | 4.92 | 4.67 | 6.65 | 6.05 | 5.87 | 3.96 | 5.82 | 6.12 |
| Tax | 0.25 | 0.21 | 0.65 | 0.55 | 0.85 | 0.88 | 0.75 | 0.75 |
| Net profit | 4.67 | 4.46 | 6.00 | 5.50 | 5.02 | 3.08 | 5.07 | 5.37 |
| EPS (₹) | 0.19 | 0.16 | 0.22 | 0.21 | 0.21 | 0.14 | 0.22 | 0.21 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 173 | 138 | 86.71 | 65.61 | 61.21 | 59.65 | 55.62 |
| Revenue growth | +25.3% | +59.0% | +32.2% | +7.2% | +2.6% | +7.3% | - |
| Other income | 8.25 | 10.43 | 4.91 | 3.95 | 1.38 | 0.52 | 1.06 |
| Total expenses | 151 | 121 | 69.68 | 60.91 | 55.84 | 53.49 | 52.37 |
| Employee cost | 0.00 | 8.35 | 7.79 | 7.87 | 6.97 | 7.21 | 6.81 |
| EBITDA | 21.84 | 16.56 | 17.03 | 4.70 | 5.37 | 6.16 | 3.25 |
| EBITDA margin | +12.6% | +12.0% | +19.6% | +7.2% | +8.8% | +10.3% | +5.8% |
| Depreciation | 2.65 | 1.99 | 2.37 | 0.92 | 0.79 | 0.88 | 1.00 |
| Interest | 4.20 | 3.61 | 3.08 | 1.35 | 0.88 | 0.74 | 0.75 |
| Profit before tax | 23.24 | 21.39 | 16.49 | 6.38 | 5.08 | 5.06 | 2.56 |
| Tax | 2.26 | 3.27 | 3.32 | 1.45 | 1.17 | 1.02 | 0.69 |
| Net profit | 19.00 | 18.26 | 12.71 | 4.89 | 3.91 | 4.32 | 1.79 |
| Net profit margin | +11.0% | +13.2% | +14.7% | +7.5% | +6.4% | +7.2% | +3.2% |
| EPS (₹) | 0.76 | 0.80 | 0.58 | 0.27 | 0.31 | 0.32 | 0.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.29 | 22.74 | 22.74 | 18.02 | 12.65 | 12.65 | 12.65 |
| Reserves & surplus | 198 | 158 | 142 | 62.33 | 31.16 | 27.06 | 23.02 |
| Shareholders' funds (net worth) | 223 | 187 | 170 | 80.35 | 43.81 | 39.71 | 35.67 |
| Minority interest | 10.32 | 7.90 | 6.08 | 6.17 | 0.00 | 0.00 | 0.00 |
| Secured loans | 35.95 | 10.22 | 5.72 | 1.05 | 10.12 | 7.36 | 4.98 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 35.95 | 10.22 | 5.72 | 1.05 | 10.12 | 7.36 | 4.98 |
| Total liabilities | 312 | 222 | 195 | 104 | 53.94 | 47.09 | 40.67 |
| Assets | |||||||
| Gross block | 84.64 | 81.37 | 75.51 | 91.51 | 30.61 | 30.34 | 30.26 |
| Net block | 60.73 | 59.55 | 55.64 | 73.73 | 13.69 | 14.12 | 14.93 |
| Capital work in progress | 13.32 | 5.22 | 2.32 | 0.02 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 6.83 | 6.83 | 6.83 |
| Inventories | 53.89 | 35.94 | 25.17 | 15.69 | 7.74 | 5.02 | 7.44 |
| Sundry debtors | 43.56 | 14.16 | 17.81 | 9.42 | 11.31 | 8.95 | 6.28 |
| Cash & bank balances | 52.42 | 55.57 | 60.97 | 15.06 | 8.31 | 1.07 | 0.91 |
| Loans & advances | 115 | 75.46 | 57.85 | 8.51 | 19.82 | 22.63 | 20.34 |
| Total current assets | 265 | 181 | 162 | 48.68 | 47.18 | 37.67 | 34.97 |
| Total current liabilities | 36.45 | 34.34 | 34.58 | 28.46 | 14.08 | 11.66 | 15.88 |
| Net working capital | 228 | 147 | 127 | 20.22 | 33.10 | 26.01 | 19.09 |
| Total assets | 312 | 222 | 195 | 104 | 53.94 | 47.09 | 40.67 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 55.57 | 60.96 | 15.06 | 8.68 | 1.07 | 0.91 | 3.15 |
| Net cash from operating activities | (63.65) | (9.56) | (46.69) | 23.68 | 11.91 | (1.44) | (1.67) |
| Net cash from investing activities | (4.80) | 2.63 | 18.91 | (38.33) | (2.47) | (0.02) | (0.22) |
| Net cash from financing activities | 65.30 | 1.53 | 73.68 | 21.03 | (1.83) | 1.62 | (0.35) |
| Net change in cash | (3.15) | (5.40) | 45.91 | 6.38 | 7.61 | 0.16 | (2.23) |
| Closing cash | 52.42 | 55.57 | 60.97 | 15.06 | 8.31 | 1.07 | 0.91 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +25.3% | +59.0% | +32.2% | +7.2% | +2.6% | +7.3% | - |
| EBITDA growth | +31.9% | -2.8% | +262.3% | -12.5% | -12.8% | +89.5% | - |
| PBT growth | +8.7% | +29.7% | +158.5% | +25.6% | +0.4% | +97.7% | -15.5% |
| Net income growth | +4.1% | +43.7% | +159.9% | +25.1% | -9.5% | +141.3% | - |
| Revenue CAGR (3Y) | +38.1% | +31.1% | +13.3% | +5.7% | +3.1% | +10.9% | +9.9% |
| EBITDA CAGR (3Y) | +66.9% | +45.6% | +40.4% | +13.1% | +10.1% | +41.2% | -10.4% |
| Profitability & leverage | |||||||
| Net income margin | +12.2% | +13.1% | +15.2% | +7.5% | +6.4% | +6.8% | +3.4% |
| Return on capital employed | - | +12.4% | +13.6% | +10.2% | +11.8% | +13.2% | +8.3% |
| Return on net worth | - | +10.2% | +10.5% | +7.9% | +9.4% | +10.7% | +5.3% |
| Debt / equity | - | 0.04 | 0.03 | 0.09 | 0.21 | 0.16 | 0.14 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 21.89 | 24.78 | 21.01 | 35.71 | 19.21 | 14.02 | 33.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.98 | 1.18 | 1.18 | 2.14 | 2.10 | 1.99 |
| Inventory turnover | - | 5.11 | 4.81 | 6.13 | 10.23 | 10.22 | 9.39 |
| Debtors turnover | - | 9.77 | 7.22 | 6.93 | 6.44 | 8.36 | 7.19 |
| EPS (₹) | 0.76 | 0.80 | 0.58 | 0.27 | 0.31 | 0.32 | 0.15 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 7.96 | 7.24 | 4.46 | 3.46 | 3.14 | 2.82 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.68 | 36.71 | 30.72 | 31.37 | 25.64 | 23.28 | 27.35 | 26.51 |
| Revenue growth (YoY) | +35.3% | +57.7% | +12.3% | +18.3% | +20.2% | - | - | - |
| Other income | 2.00 | 1.30 | 0.00 | 0.00 | 2.26 | 2.87 | 0.00 | 0.00 |
| Total expenses | 31.72 | 33.83 | 24.86 | 25.37 | 22.26 | 23.21 | 21.78 | 20.98 |
| EBITDA | 2.96 | 2.88 | 5.86 | 6.00 | 3.38 | 0.07 | 5.57 | 5.53 |
| EBITDA margin | +8.5% | +7.8% | +20.8% | +20.5% | +13.2% | +0.3% | +22.0% | +22.4% |
| Depreciation | 0.24 | 0.35 | 0.21 | 0.21 | 0.20 | 0.53 | 0.20 | 0.05 |
| Interest | 0.51 | 0.63 | 0.69 | 0.55 | 0.59 | 0.23 | 0.41 | 0.47 |
| Profit before tax | 4.21 | 3.20 | 4.96 | 5.24 | 4.85 | 2.18 | 4.96 | 5.01 |
| Tax | 0.25 | 0.21 | 0.50 | 0.70 | 0.70 | 0.67 | 0.75 | 0.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 120 | 94.58 | 66.80 | 65.10 | 61.21 | 59.65 | 55.62 |
| Revenue growth | +26.7% | +41.6% | +2.6% | +6.4% | +2.6% | +7.3% | - |
| Other income | 8.14 | 9.22 | 4.30 | 3.40 | 1.38 | 0.52 | 1.06 |
| Total expenses | 106 | 84.39 | 54.37 | 60.51 | 55.84 | 53.49 | 52.37 |
| Employee cost | 0.00 | 6.42 | 6.05 | 7.71 | 6.97 | 7.21 | 6.81 |
| EBITDA | 13.53 | 10.19 | 12.43 | 4.59 | 5.37 | 6.16 | 3.25 |
| EBITDA margin | +11.3% | +10.8% | +18.6% | +7.1% | +8.8% | +10.3% | +5.8% |
| Depreciation | 0.97 | 0.77 | 0.81 | 0.74 | 0.79 | 0.88 | 1.00 |
| Interest | 2.47 | 1.58 | 1.16 | 1.23 | 0.88 | 0.74 | 0.75 |
| Profit before tax | 18.23 | 17.06 | 14.76 | 6.02 | 5.08 | 5.06 | 2.56 |
| Tax | 2.11 | 3.02 | 2.96 | 1.45 | 1.17 | 1.02 | 0.69 |
| Net profit | 16.65 | 14.18 | 11.80 | 4.53 | 3.91 | 4.32 | 1.79 |
| Net profit margin | +13.9% | +15.0% | +17.7% | +7.0% | +6.4% | +7.2% | +3.2% |
| EPS (₹) | 0.67 | 0.62 | 0.52 | 0.25 | 0.31 | 0.32 | 0.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.29 | 22.74 | 22.74 | 18.02 | 12.65 | 12.65 | 12.65 |
| Reserves & surplus | 194 | 156 | 142 | 61.00 | 31.35 | 27.24 | 23.20 |
| Shareholders' funds (net worth) | 218 | 185 | 171 | 79.02 | 44.00 | 39.89 | 35.85 |
| Secured loans | 22.82 | 1.24 | 0.85 | 0.98 | 10.12 | 7.36 | 4.98 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 22.82 | 1.24 | 0.85 | 0.98 | 10.12 | 7.36 | 4.98 |
| Total liabilities | 245 | 191 | 173 | 81.29 | 54.12 | 47.25 | 40.85 |
| Assets | |||||||
| Gross block | 41.42 | 38.60 | 34.08 | 32.62 | 30.61 | 30.34 | 30.26 |
| Net block | 21.64 | 19.66 | 15.83 | 15.18 | 13.69 | 14.12 | 14.93 |
| Capital work in progress | 5.18 | 2.62 | 1.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 8.26 | 8.26 | 8.26 | 8.26 | 7.01 | 7.01 | 7.01 |
| Inventories | 41.63 | 24.59 | 16.07 | 14.97 | 7.74 | 5.02 | 7.44 |
| Sundry debtors | 33.37 | 11.89 | 13.57 | 8.82 | 11.31 | 8.95 | 6.28 |
| Cash & bank balances | 52.40 | 55.56 | 60.96 | 14.45 | 8.31 | 1.07 | 0.91 |
| Loans & advances | 111 | 94.98 | 88.39 | 33.91 | 19.82 | 22.63 | 20.34 |
| Total current assets | 238 | 187 | 179 | 72.15 | 47.18 | 37.67 | 34.97 |
| Total current liabilities | 29.26 | 27.87 | 31.97 | 14.93 | 14.08 | 11.68 | 15.88 |
| Net working capital | 209 | 159 | 147 | 57.22 | 33.10 | 25.99 | 19.09 |
| Total assets | 245 | 191 | 173 | 81.29 | 54.12 | 47.25 | 40.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 55.60 | 60.96 | 14.45 | 8.31 | 1.07 | 0.91 | 3.15 |
| Net cash from operating activities | (40.18) | (9.52) | (33.43) | (14.45) | 6.64 | (1.44) | (1.67) |
| Net cash from investing activities | 1.62 | 2.63 | 0.93 | (0.77) | (1.26) | (0.02) | (0.22) |
| Net cash from financing activities | 35.40 | 1.53 | 79.01 | 21.35 | 1.87 | 1.62 | (0.35) |
| Net change in cash | (3.16) | (5.36) | 46.51 | 6.14 | 7.24 | 0.16 | (2.23) |
| Closing cash | 52.40 | 55.56 | 60.96 | 14.45 | 8.31 | 1.07 | 0.91 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +26.7% | +41.6% | +2.6% | +6.4% | +2.6% | +7.3% | - |
| EBITDA growth | +32.8% | -18.0% | +170.8% | -14.5% | -12.8% | +89.5% | - |
| PBT growth | +6.9% | +15.6% | +145.2% | +18.5% | +0.4% | +97.7% | -15.5% |
| Net income growth | +17.4% | +20.2% | +160.5% | +15.9% | -9.5% | +141.3% | - |
| Revenue CAGR (3Y) | +22.6% | +15.6% | +3.9% | +5.4% | +3.1% | +10.9% | +9.9% |
| EBITDA CAGR (3Y) | +43.4% | +23.8% | +26.4% | +12.2% | +10.1% | +41.2% | -10.4% |
| Profitability & leverage | |||||||
| Net income margin | +13.5% | +14.8% | +17.7% | +7.0% | +6.4% | +6.8% | +3.4% |
| Return on capital employed | - | +10.3% | +12.5% | +10.7% | +11.8% | +13.2% | +8.3% |
| Return on net worth | - | +7.9% | +9.5% | +7.4% | +9.4% | +10.7% | +5.3% |
| Debt / equity | - | 0.01 | 0.01 | 0.09 | 0.21 | 0.16 | 0.14 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 19.67 | 16.77 | 9.98 | 31.95 | 19.21 | 14.02 | 33.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 2.89 | 2.22 | 2.26 | 2.14 | 2.10 | 1.99 |
| Inventory turnover | - | 5.17 | 4.77 | 6.28 | 10.23 | 10.22 | 9.39 |
| Debtors turnover | - | 8.26 | 6.61 | 7.09 | 6.44 | 8.36 | 7.19 |
| EPS (₹) | 0.67 | 0.62 | 0.52 | 0.25 | 0.31 | 0.32 | 0.15 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 7.87 | 7.26 | 4.39 | 3.48 | 3.15 | 2.83 |
To see the full year-wise statements and ratios of Gennex Laboratories Limited, buy the company report.
Board of directors of Gennex Laboratories Limited
Gennex Laboratories has 6 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ranga Rao Pantulu Avasarala | Director | 21 Dec 2020 | 5 Years 10 Months | Current |
| Arihant Baid Also directs: Boujee Foods LLP, Prudential Holdings Pvt. Ltd., Vab Realty Private Limited and 4 more | Managing Director | 18 May 2012 | 14 Years 5 Months | Current |
| Amudala Sreeramulu Nageswar Rao | Director | 21 Dec 2020 | 5 Years 10 Months | Current |
| Sandeep Kumar Daga Also directs: Prudential Sugar Corporation Limited | Director | 30 May 2025 | 1 Years 4 Months | Current |
| Dilip Raj Singhvi Also directs: Regium Crafts LLP, Vibes Green Energy LLP, Helios Solar Technologies Private Limited and 2 more | Director | 01 Oct 2024 | 2 Years 0 Months | Current |
| Khushbu Kachhawa Also directs: Snehaa Organics Limited | Director | 14 Feb 2026 | 0 Years 8 Months | Current |
Peer comparison
Gennex Laboratories Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Gennex Laboratories Limitedthis company | ₹172.74 Cr (FY 2026) | ₹19 Cr | 11% | 25.3% | 103 | Medak, Telangana, India |
| Angels Pharma India Private Limited | ₹94.49 Cr (FY 2021) | 636.0% | Hyderabad, Telangana, India | |||
| Polypeptide Laboratories Private Limited | ₹94.1 Cr (FY 2025) | 34.0% | Ambernath, Maharashtra, India | |||
| Integrin Lifesciences Private Limited | ₹92.04 Cr (FY 2025) | 3.0% | Hyderabad, Telangana, India | |||
| Brichem Sciences Private Limited | ₹91.35 Cr (FY 2025) | 16.0% | Ahmedabad, Gujarat, India | |||
| Modepro (India) Pvt Ltd | ₹91.12 Cr (FY 2025) | -14.0% | Mumbai, Maharashtra, India | |||
| Pab Organics Private Limited | ₹90.32 Cr (FY 2025) | 11.0% | Vadodara, Gujarat, India | |||
| Verdant Life Sciences Private Limited | ₹89.48 Cr (FY 2025) | 6.0% | Andhra Pradesh, India | |||
| Medilux Laboratories Pvt Ltd | ₹89.42 Cr (FY 2018) | -2.0% | Indore, Madhya Pradesh, India |
To see the full peer comparison of Gennex Laboratories Limited, buy the company report.
Auditor
Gennex Laboratories Limited is audited by PPKG & Co., for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PPKG & Co., | FY 2023 | 009655S |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 23.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 76.40%.
Mar 2026
QUARTER
23.60% Promoters
76.40% Retail & Others
Promoter holding - history
Now 23.60% · Mar 2026High 23.60% · Sep 2025Low 19.80% · Jun 2025
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 23.60% | 23.60% | 23.60% | 19.80% |
| Public | 76.40% | 76.40% | 76.40% | 80.20% |
Charges & borrowings
Open charges
₹66 Cr
Satisfied charges
₹26.13 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 17 Jan 2026 | 101264561 | Hdfc Bank Limited | ₹25 Lakh | Open | |
| 24 Sep 2025 | 101170708 | Others | ₹1.5 Cr | Open | |
| 22 Nov 2024 | 101008332 | Others | ₹6.65 Cr | Open | |
| 01 Oct 2024 | 100995451 | Others | ₹5 Cr | Open | |
| 31 Oct 2023 | 100848978 | Others | ₹22.5 Lakh | Open |
To see the full charge records of Gennex Laboratories Limited, buy the company report.
Total charge records: 12 View all charges
Deals & funding
Gennex Laboratories Limited has 160 deals on record (158 market trades, 2 rights issues); the latest was in May 2026.
Total deals
160
Market trades
158
Rights issues
2
Deals on record (5 of 160)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2026 | Market trade | ₹1.52 Cr | Buyer: Anupriya Consultants Pvt Ltd Seller: Anupriya Consultants Pvt Ltd |
| May 2026 | Market trade | ₹1.93 Cr | Buyer: Anupriya Consultants Pvt Ltd |
| Oct 2025 | Market trade | ₹2.07 Cr | Buyer: Dorite Tracon Pvt Ltd Seller: Kamal Kumar Dugar And Co ( Prop : Kamal Kumar Dugar) |
| Oct 2025 | Market trade | ₹2.67 Cr | Buyer: Narantak Dealcomm Ltd |
| Sep 2025 | Market trade | ₹1.87 Cr | Seller: Tropical Agro System (India) Private Limited |
To see the full deal history of Gennex Laboratories Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Gennex Laboratories Limited has 30 court cases on record: 18 filed by Gennex Laboratories, 12 filed against it. 3 cases are pending and 27 are disposed.
Total cases
30
Filed by the company
18
Filed against the company
12
Pending
3
Disposed
27
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 18 | 5 | 2 |
| District courts | 10 | 7 | 1 |
| Supreme Court | 2 | 0 | 0 |
Cases on record (5 of 30)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Hyderabad CCC, Telangana | Civil suit | Filed by the company against Hanaro Logistics Private Limited | Disposed |
| District court, Chennai, Tamil Nadu | Criminal complaint | Filed against the company by M/S. Pon Pure Chemicals India Private Limited Rep. by. Jino Antony | Disposed |
| District court, Hyderabad CCC, Telangana | Court case (AS) | Filed by the company against Bajaj Organics Pvtltd., | Disposed |
| High Court, TELANGANA | Company petition | Filed against the company by M/S Granules India Ltd | Disposed |
| District court, KOLAR, Karnataka | Civil suit | Filed against the company by M/S. Vinayaka Plastics | Pending |
To see the full case history of Gennex Laboratories Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Gennex Laboratories Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Gennex Laboratories has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Deccan Remedies Limited | U72200TG1994PLC016962 |
To see the full group structure of Gennex Laboratories Limited, buy the company report.
Employees & EPFO
Gennex Laboratories Limited has a workforce of 103 employees on its EPFO records as of Mar 30, 2024, across 1 active EPFO establishment.
Employee count
103
Active EPFO establishments
1
Employee growth
5.1%
GST
Gennex Laboratories has 2 GST registrations on record, and all of them have been cancelled or are inactive. Only active GST numbers are listed on this page.
Total GSTINs
2
Cancelled / inactive
2
To see the full GST registrations and return filing status of Gennex Laboratories Limited, buy the company report.
Recent activity
Gennex Laboratories Limited has 32 board changes on record since 1995: 20 appointments and 12 cessations. The latest: Khushbu Kachhawa was appointed as Director on 14 Feb 2026.
Filing
Gennex Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Appointed
Khushbu Kachhawa was appointed as Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.25 Cr with Charge ID 101264561 was registered on 17 Jan 2026.
AGM
Gennex Laboratories Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 1.50 Cr with Charge ID 101170708 was registered on 24 Sep 2025.
Charges
A charge with Others of Rs. 30.00 Cr registered on 07 Feb 2023 with Charge ID 100693118 was modified on 24 Sep 2025.
Ceased
China Dharma Rao Sangeetrao ceased to be Director.
Appointed
Sandeep Kumar Daga was appointed as Director.
Ceased
Mohammed Khaleequr Rahman ceased to be Director.
Charges
A charge with Others amounted to Rs. 6.65 Cr with Charge ID 101008332 was registered on 22 Nov 2024.
Charges
A charge with Others amounted to Rs. 5.00 Cr with Charge ID 100995451 was registered on 01 Oct 2024.
Appointed
Dilip Raj Singhvi was appointed as Director.
40 earlier events are in the company report.
News
Frequently asked questions
Gennex Laboratories is an active public limited company based in Medak, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 29 March 1990 (36+ years old) and is registered under CIN L24230TG1990PLC011168. Listed on BSE: 531739.
Gennex Laboratories reported revenue of ₹172.74 Cr for FY 2025-26 (up 25.3% YoY) based on consolidated financials.
Gennex Laboratories has 6 current directors:
- Arihant Baid - Managing Director
- Ranga Rao Pantulu Avasarala - Director
- Amudala Sreeramulu Nageswar Rao - Director
- Sandeep Kumar Daga - Director
- Dilip Raj Singhvi - Director
- Khushbu Kachhawa - Director
The latest financial statements of Gennex Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
No. Gennex Laboratories has 2 GST registrations on record and all of them are cancelled or inactive.
The CIN (Corporate Identification Number) of Gennex Laboratories is L24230TG1990PLC011168. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Gennex Laboratories is a listed company as per MCA records. Its shares are listed on BSE (code: 531739).
Gennex Laboratories has 30 court cases on record: 18 filed by the company and 12 filed against it. 3 are pending. Most are in the high courts.
Gennex Laboratories was incorporated on 29 March 1990, making it 36+ years old. It is registered with the Registrar of Companies, Hyderabad.
Gennex Laboratories has 160 deals on record (158 market trades, 2 rights issues); the latest was in May 2026.
The peers of Gennex Laboratories by revenue are Angels Pharma India Private Limited, Polypeptide Laboratories Private Limited, Integrin Lifesciences Private Limited, Brichem Sciences Private Limited, Modepro (India) Pvt Ltd and 3 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).